Kishore Guda, DVM, PhD, an associate professor of oncology at Case Western Reserve University School of Medicine, has been awarded $200,000 by The DeGregorio Family Foundation and the Price Family Foundation—partnering with the Savone Family and The Esophageal Cancer Awareness Association.
This award will support Dr. Guda's research at the Case Comprehensive Cancer Center on establishing a deeper understanding of the TGFbeta cellular pathway and its impact on the development of esophageal adenocarcinoma (EAC).
EAC is a highly deadly cancer, the incidence of which has increased more than fivefold in the past three decades, the fastest for any solid tumor. The prognosis for EAC patients remains poor, with five-year survival remaining a dismally low 18%.
Therapeutic options for patients with EAC are very limited, with the majority of these cancers developing resistance to standard chemoradiation treatments. Targeted therapies, on the other hand, are virtually non-existent. Inadequate understanding of the mechanisms driving EAC progression has limited the development of effective prevention, detection, and targeted treatment strategies—and is a critical unmet clinical need in this lethal malignancy.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox! Sign up now!
Dr. Guda's research has led to the discovery that the growth of EACs is dependent on cellular pathways, including TGFbeta—this pathway switches from being a growth suppressor to growth promoter during the development of EAC, contrary to its function in other gastrointestinal cancers.
With this grant, Dr. Guda will pursue mechanistic studies to comprehensively dissect the paradoxical effects of the TGFbeta pathway in this disease and will assess the anti-tumor efficacy of a new generation of pharamacologic agents targeting the TGFbeta-pathway in preclinical animal models. These proposed studies seek to unravel novel mechanisms driving EAC progression, as well as lay the framework for subsequent clinical trials to evaluate anti-TGFbeta therapy as a new targeted-treatment approach in esophageal cancer patients.
"We are pleased to receive this generous support from the DeGregorio Family Foundation that will enable us to evaluate new treatment modalities for combating this increasingly prevalent and deadly cancer," Dr. Guda said.